Nephrotoxic Biomarkers with Specific Indications for Metallic Pollutants: Implications for Environmental Health

por Pócsi, István, Dockrell, Mark E, Price, Robert G
Publicado 2022

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing

por Best, Nicky, Price, Robert G., Pouliquen, Isabelle J., Keene, Oliver N.
Publicado 2021

Urinary Biomarkers of Mycotoxin Induced Nephrotoxicity—Current Status and Expected Future Trends

por Ráduly, Zsolt, Price, Robert G., Dockrell, Mark E. C., Csernoch, László, Pócsi, István
Publicado 2021

The role of urinary N-acetyl-β-D-glucosaminidase in early detection of acute kidney injury among pediatric patients with neoplastic disorders in a retrospective study

por Bíró, Erika, Szegedi, István, Kiss, Csongor, Oláh, Anna V., Dockrell, Mark, Price, Robert G., Szabó, Tamás
Publicado 2022

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis

por Prazma, Charlene M., Bel, Elisabeth H., Price, Robert G., Bradford, Eric S., Albers, Frank C., Yancey, Steven W.
Publicado 2019

New perspectives in application of kidney biomarkers in mycotoxin induced nephrotoxicity, with a particular focus on domestic pigs

por Ráduly, Zsolt, Szabó, András, Mézes, Miklós, Balatoni, Ildikó, Price, Robert G., Dockrell, Mark E., Pócsi, István, Csernoch, László
Publicado 2023

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma

por Gupta, Atul, Pouliquen, Isabelle, Austin, Daren, Price, Robert G., Kempsford, Rodger, Steinfeld, Jonathan, Bradford, Eric S., Yancey, Steven W.
Publicado 2019

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports

por Pini, Laura, Caruso, Cristiano, Colantuono, Stefania, Bagnasco, Diego, Maxwell, Aoife, Price, Robert G., Howarth, Peter, Canonica, Giorgio Walter
Publicado 2021

Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma

por Korn, Stephanie, Howarth, Peter, Smith, Steven G., Price, Robert G., Yancey, Steven W., Prazma, Charlene M., Bel, Elisabeth H.
Publicado 2022

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab

por Pavord, Ian D., Buhl, Roland, Kraft, Monica, Prazma, Charlene M., Price, Robert G., Howarth, Peter H., Yancey, Steven W.
Publicado 2022

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

por Chapman, Kenneth R., Albers, Frank C., Chipps, Bradley, Muñoz, Xavier, Devouassoux, Gilles, Bergna, Miguel, Galkin, Dmitry, Azmi, Jay, Mouneimne, Dalal, Price, Robert G., Liu, Mark C.
Publicado 2019

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET

por Liu, Mark C., Bel, Elisabeth H., Kornmann, Oliver, Moore, Wendy C., Kaneko, Norihiro, Smith, Steven G., Martin, Neil, Price, Robert G., Yancey, Steven W., Humbert, Marc
Publicado 2022

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

por Pavord, Ian, Gardiner, Frances, Heaney, Liam G., Domingo, Christian, Price, Robert G., Pullan, Alison, Oppenheimer, John, Brusselle, Guy, Nagase, Hiroyuki, Chupp, Geoffrey, Pizzichini, Emilio, Bañas-Conejero, David, Howarth, Peter
Publicado 2023

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

por Liu, Mark C., Chipps, Bradley, Munoz, Xavier, Devouassoux, Gilles, Bergna, Miguel, Smith, Steven G., Price, Robert G., Galkin, Dmitry V., Azmi, Jay, Mouneimne, Dalal, Albers, Frank C., Chapman, Kenneth R.
Publicado 2021

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)

por Moore, Wendy C., Kornmann, Oliver, Humbert, Marc, Poirier, Claude, Bel, Elisabeth H., Kaneko, Norihiro, Smith, Steven G., Martin, Neil, Gilson, Martyn J., Price, Robert G., Bradford, Eric S., Liu, Mark C.
Publicado 2022